Patient Goals Should Figure Prominently in Tx Discussions
Wanted: Physicians who will interact with patients the way a good financial counselor would.
Prostate Cancer Treatments Abundant, Not Perfect
A range of options for metastatic castration resistant prostate cancer offer benefits, but impact on survival and sequencing guidance are less than optimal.
No Added Prostate Cancer Risk With Long-term Testosterone Tx
Risk does not go up with exposure to testosterone therapy over a 5-year period or according to total testosterone injections.
Safest for Favorable-risk Prostate Cancer: Surveillance
The goal is to avoid treating men who don’t need surgery or radiation. A new long-term study points to the potential of surveillance as a treatment option.
Paradox: Asthma Resists Lethal Prostate Cancer
Lethal prostate cancer is less—not more—likely to develop in patients with asthma. The Health Professionals Follow-up Study answers key questions about why.
Where You Live Affects How Inappropriately Imaging is Used
Inappropriate imaging for low-risk prostate cancer and low-risk breast cancer varies by region.
Baldness in Middle Age May Be Linked to Aggressive Prostate Cancer
A large trial found that men with moderate baldness at age 45 had an increased risk of developing aggressive prostate cancer compared with men with no baldness.
Commentary on the USPF's Recommendations on PSA Testing
A video series from James Mohler of Rosweel Park Cancer Institute on PSA testing in the wake of changing guidelines from the US Preventive Task Force.
Video: Who's at Risk for Prostate Cancer?
James Mohler, MD, Roswell Park Cancer Institue, discusses risk factors for prostate cancer.
Video: What To Tell Your Patients About PSA Testing
James Mohler, MD, Roswell Park Cancer Institute, defines who is at risk for prostate cancer, how to decide who should be screened, and how to talk to patients about the test and their results.
Video: Criticism of the US Task Force Preventive Services Taskforce Study of PSA Testing
James Mohler, MD, of Roswell Park Cancer Institute, points out the flaws in the TaskForce analysis.
By clicking Accept, you agree to become a member of the UBM Medica Community.